Cytomegalovirus coinfection in patients with severe acute respiratory syndrome coronavirus 2 infection: a systematic review of reported cases

References

• Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.
   PubMed Web of Science ®Google Scholar
• Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288–297.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121(5):1673–1680.
   PubMed Web of Science ®Google Scholar
• Chiche L, Forel J-M, Roch A, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37:1850–1857.
   PubMed Web of Science ®Google Scholar
• Chiche L, Forel J-M, Thomas G, et al. Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients. Crit Care Med. 2012;40(12):3162–3169.
   PubMedGoogle Scholar
• Ziemann M, Sedemund-Adib B, Reiland P, et al. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med. 2008;36:3145–3150.
   PubMedGoogle Scholar
• Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254–266.
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun J, Dai Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol. 2020;127:104371.
   PubMed Web of Science ®Google Scholar
• Jamal M, Bangash HI, Habiba M, et al. Immune dysregulation and system pathology in COVID-19. Virulence. 2021;12(1):918–936.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, PRISMA-P Group, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Niitsu T, Shiroyama T, Hirata H, et al. Cytomegalovirus infection in critically ill patients with COVID-19. J Infect. 2021;83(4):496–522.
   PubMedGoogle Scholar
• Carll WC, Rady MY, Salomao MA, et al. Cytomegalovirus haemorrhagic enterocolitis associated with severe infection with COVID-19. BMJ Open Gastroenterol. 2021;8(1):e000556.
   PubMedGoogle Scholar
• Szafron V, Pereira M, Vogel T, et al. A balancing act: treatment of COVID-19 and cytomegalovirus in a patient with primary immunodeficiency. Ann Allergy Asthma Immunol. 2020;125(5):S106–S107.
   Google Scholar
• Shah M, Kakar A, Gogia A, et al. Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link? J Postgrad Med. 2021;67(2):100–102.
   PubMedGoogle Scholar
• Marchi G, Vianello A, Crisafulli E, et al. Cytomegalovirus-induced gastrointestinal bleeding and pancreatitis complicating severe Covid-19 pneumonia: a paradigmatic case. Mediterr J Hematol Infect Dis. 2020;12(1):e2020060.
   PubMedGoogle Scholar
• Amaral PH, Ferreira BM, Roll S, et al. COVID-19 and cytomegalovirus co-infection: a challenging case of a critically ill patient with gastrointestinal symptoms. Eur J Case Rep Intern Med. 2020;7(10):001911.
   PubMedGoogle Scholar
• Geisen WR, Berger J, Schwartz C, et al. Cytomegalovirus enterocolitis secondary to experimental COVID-19 therapy. IDCases. 2020;22:e00962.
   PubMedGoogle Scholar
• Huang SW, Lin SE, Lee CS, et al. Cytomegalovirus colitis combined with Clostridium innocuum as a cause of lower GI bleeding in a patient with COVID-19. Gastrointest Endosc. 2021;95(2):388–390.
   Google Scholar
• Yoshida N, Hirose R, Watanabe M, et al. A case of urgent colonoscopic hemostasis of a cecal hemorrhagic ulceration in a patient receiving heparin for COVID-19 coagulopathy. JGH Open. 2021;5(1):160–162.
   PubMedGoogle Scholar
• Leemans S, Maillart E, Van Noten H, et al. Cytomegalovirus haemorrhagic colitis complicating COVID-19 in an immunocompetent critically ill patient: a case report. Clin Case Rep. 2021;9(5):e03600.
   PubMedGoogle Scholar
• Khatib MY, Shaik KS, Ahmed AA, et al. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19. Clin Case Rep. 2021;9(1):148–152.
   PubMedGoogle Scholar
• Maillet F, Pourbaix A, le Pluart D, et al. Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments. IDCases. 2021;24:e01111.
   PubMedGoogle Scholar
• Silvano J, Ferreira F, Bustorff M, et al. Viral clearance and serological response to SARS-CoV-2 in kidney transplant recipients. Transplant Proc. 2021;53(4):1180–1186.
   PubMedGoogle Scholar
• Selvaraj V, Moustafa A, Dapaah-Afriyie K, et al. COVID-19-induced granulomatosis with polyangiitis. BMJ Case Rep. 2021;14(3):e242142.
   PubMedGoogle Scholar
• Jiwa N, Lorick K, Mutneja R. Cytomegalovirus colitis post IL-6 inhibitor use in COVID-19 infection. Chest. 2020;158(4):A772–772A.
   Google Scholar
• Amiya S, Hirata H, Shiroyama T, et al. Fatal cytomegalovirus pneumonia in a critically ill patient with COVID-19. Respirol Case Rep. 2021;9:e00801.
   PubMedGoogle Scholar
• Merchant EA, Flint K, Barouch DH, et al. Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome. IDCases. 2021;24:e01153.
   PubMed Web of Science ®Google Scholar
• Shaikh AS, Shaim H, Caravedo MA, et al. A new viral coinfection: SARS-CoV-2 pneumonia and cytomegalovirus pneumonitis in a renal transplant recipient. COVID. 2021;1(1):115–119.
   Google Scholar
• Pandian E, D'Souza G. COVID-19 pneumonia complicated by CMV pneumonitis following treatment with an IL-6 inhibitor. Chest. 2021;160(4):A339–339A.
   Google Scholar
• Moniz P, Brito S, Póvoa P. SARS-CoV-2 and cytomegalovirus co-infections—a case series of critically ill patients. J Clin Med. 2021;10:2792.
   PubMedGoogle Scholar
• Rizvi A, Mujtaba M, Gamilla-Crudo A, et al. Coinfection with COVID-19 and cytomegalovirus in kidney transplant recipients - a case series. Am J Kidney Dis. 2021;77:642–642.
   Google Scholar
• D'Ardes D, Boccatonda A, Schiavone C, et al. A case of coinfection with SARS-COV-2 and cytomegalovirus in the era of COVID-19. Eur J Case Rep Intern Med. 2020;7(5):001652.
   PubMedGoogle Scholar
• Liroff K, Fleury C, Dumitrescu C, et al. Delayed onset of COVID-19 in an immunosuppressed patient. Infect Dis Clin Pract. 2021;29(6):e448–e450.
   PubMedGoogle Scholar
• Ananthegowda DC, Khatib MY, Ali HS, et al. Cytomegalovirus meningoencephalitis in a case of severe COVID-19 pneumonia. A case report. IDCases. 2021;26:e01346.
   PubMedGoogle Scholar
• Lim TH, Wai YZ, Chong JC. Unilateral frosted branch angiitis in an human immunodeficiency virus-infected patient with concurrent COVID-19 infection: a case report. J Med Case Rep. 2021;15:267.
   PubMedGoogle Scholar
• Amundson L, Boelts B, Kataria V, et al. Ganciclovir therapy for CMV viremia in a patient on VV ECMO with COVID-19 after treatment with tocilizumab. Infect Dis Clin Pract. 2021;29(3):E191–E192.
   Google Scholar
• Maritati F, Moretti MI, Nastasi V, et al. ANCA-Associated glomerulonephritis and anti-phospholipid syndrome in a patient with SARS-CoV-2 infection: just a coincidence? Case Rep Nephrol Dial. 2021;11(2):214–220.
   PubMedGoogle Scholar
• Molaei H, Khedmat L, Nemati E, et al. Iranian kidney transplant recipients with COVID-19 infection: clinical outcomes and cytomegalovirus coinfection. Transpl Infect Dis. 2021;23(1):e13455.
   PubMed Web of Science ®Google Scholar
• Koca A, Talan L, Şahin T, et al. An unusual course of SARS-CoV-2 infection: challenging diagnosis of Guillain-Barré syndrome. Tuberk Toraks. 2021;69(2):242–246.
   PubMedGoogle Scholar
• Gozzi-Silva SC, Benard G, Alberca RW, et al. SARS-CoV-2 infection and CMV dissemination in transplant recipients as a treatment for chagas cardiomyopathy: a case report. Trop Med Infect Dis. 2021;6:22.
   PubMedGoogle Scholar
• Vigón L, García-Pérez J, Rodríguez-Mora S, et al. Impaired antibody-dependent cellular cytotoxicity in a Spanish cohort of patients with COVID-19 admitted to the ICU. Front Immunol. 2021;12:742631.
   PubMedGoogle Scholar
• Dogan L, Kaya D, Sarikaya T, et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun. 2020;87:155–158.
   PubMed Web of Science ®Google Scholar
• Maritati F, Cerutti E, Zuccatosta L, et al. SARS-CoV-2 infection in kidney transplant recipients: experience of the italian Marche region. Transpl Infect Dis. 2020;22(5):e13377
   PubMedGoogle Scholar
• Sugawara-Mikami M, Ishii N, Yamazaki M, et al. Skin manifestations of suspected COVID-19: complications of the disease or reactivation of latent viral infections? JAAD Case Rep. 2021;12:15–17.
   PubMedGoogle Scholar
• Taherifard E, Taherifard E, Movahed H, et al. Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. Hematology. 2021;26(1):225–239.
   PubMed Web of Science ®Google Scholar
• Thakur V, Ratho RK, Kumar P, et al. Multi-organ involvement in COVID-19: beyond pulmonary manifestations. J Clin Med. 2021;10:446.
   PubMed Web of Science ®Google Scholar
• Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program. 2011;2011:305–309.
   PubMed Web of Science ®Google Scholar
• Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e2011335–e2011335.
   PubMed Web of Science ®Google Scholar
• Aguila EJT, Cua IHY, Fontanilla JAC, et al. Causing MFP; gastrointestinal manifestations of COVID-19: impact on nutrition practices. Nutr Clin Pract. 2020;35(5):800–805.
   PubMedGoogle Scholar
• Zeng W, Qi K, Ye M, et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(2):168–176.
   PubMedGoogle Scholar
• Shaiegan M, Rasouli M, Zadsar M, et al. Meta-analysis of cytomegalovirus seroprevalence in volunteer blood donors and healthy subjects in Iran from 1992 to 2013. Iran J Basic Med Sci. 2015;18(7):627–634.
   PubMed Web of Science ®Google Scholar
• Kasper D, Fauci A, Hauser S, et al. Harrison's principles of internal medicine, 19e. New York (NY): Mcgraw-Hill; 2015.
   Google Scholar
• Herndler-Brandstetter D. How aging affects T lymphocyte-mediated immunity. Front Immunol. 2013;4:296–296.
   PubMedGoogle Scholar
• Asberg A, Jardine AG, Bignamini AA et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant. 2010;10(8):1881–1888.
   PubMedGoogle Scholar
• Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and b lymphocytes to the bone marrow. Immunology. 1975; [Database]28:669–680.
   PubMed Web of Science ®Google Scholar
• Zweiman B, Atkins PC, Bedard PM, et al. Corticosteroid effects on circulating lymphocyte subset levels in normal humans. J Clin Immunol. 1984;4(2):151–155.
   PubMedGoogle Scholar
• Troselj-Vukic B, Milotic I, Milotic F, et al. Cytomegalovirus reactivation after low-dose steroid treatment for hemolytic anemia in a patient with primary Epstein-Barr virus infection. Wien Klin Wochenschr. 2007;119(13–14):435–437.
   PubMedGoogle Scholar
• Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol. 2006;97(1):113–116.
   PubMedGoogle Scholar
• Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis. 2020;96:131–135.
   PubMed Web of Science ®Google Scholar
• He R, Lu Z, Zhang L, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020;127:104361–104361.
   PubMed Web of Science ®Google Scholar
• Söderberg-Nauclér C. Does reactivation of cytomegalovirus contribute to severe COVID-19 disease? Immun Ageing. 2021;18(1):12.
   PubMedGoogle Scholar
• Li X, Huang Y, Xu Z, et al. Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):289.
   PubMedGoogle Scholar
• Yamamoto Y, Shiroyama T, Hirata H, et al. Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. J Med Virol. 2021;94:1067–1073.
   PubMedGoogle Scholar
• Cowley NJ, Owen A, Shiels SC, et al. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med. 2017;177(6):774–783.
   PubMedGoogle Scholar